These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 24148310)

  • 21. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
    Mahmud SM; Kliewer EV; Lambert P; Bozat-Emre S; Demers AA
    J Clin Oncol; 2014 Feb; 32(5):438-43. PubMed ID: 24395857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
    Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women.
    Innes CR; Williman JA; Simcock BJ; Hider P; Sage M; Dempster-Rivett K; Lawton BA; Sykes PH
    N Z Med J; 2020 Jan; 133(1508):72-84. PubMed ID: 31945044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
    Falcaro M; Soldan K; Ndlela B; Sasieni P
    BMJ; 2024 May; 385():e077341. PubMed ID: 38749552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta.
    Kim J; Bell C; Sun M; Kliewer G; Xu L; McInerney M; Svenson LW; Yang H
    CMAJ; 2016 Sep; 188(12):E281-E288. PubMed ID: 27378467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
    Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
    BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity.
    Kudo R; Sekine M; Yamaguchi M; Hara M; Hanley SJB; Kurosawa M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
    Cancer Sci; 2022 Sep; 113(9):3211-3220. PubMed ID: 35730321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination.
    Dong L; Nygård M; Støer NC; Klungsøyr O; Hansen BT
    Int J Cancer; 2023 Jul; 153(2):399-406. PubMed ID: 36866965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
    Inturrisi F; Lissenberg-Witte BI; Veldhuijzen NJ; Bogaards JA; Ronco G; Meijer CJLM; Berkhof J
    Int J Cancer; 2021 Jan; 148(2):320-328. PubMed ID: 32663316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study.
    Herweijer E; Feldman AL; Ploner A; Arnheim-Dahlström L; Uhnoo I; Netterlid E; Dillner J; Sparén P; Sundström K
    PLoS One; 2015; 10(7):e0134185. PubMed ID: 26218492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus vaccine effectiveness within a cervical cancer screening programme: cohort study.
    Acuti Martellucci C; Nomura S; Yoneoka D; Ueda P; Brotherton J; Canfell K; Palmer M; Manzoli L; Giorgi Rossi P; De Togni A; Palmonari C; Califano A; Saito E; Hashizume M; Shibuya K
    BJOG; 2021 Feb; 128(3):532-539. PubMed ID: 32779381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
    Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
    Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study.
    Martellucci CA; Morettini M; Brotherton JML; Canfell K; Manzoli L; Flacco ME; Palmer M; Rossi PG; Martellucci M; Giacomini G; D'Errico MM; Pasqualini F
    Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):588-594. PubMed ID: 35027435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.
    Crowe E; Pandeya N; Brotherton JM; Dobson AJ; Kisely S; Lambert SB; Whiteman DC
    BMJ; 2014 Mar; 348():g1458. PubMed ID: 24594809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study.
    Verdoodt F; Dehlendorff C; Kjaer SK
    Clin Infect Dis; 2020 Feb; 70(4):608-614. PubMed ID: 30892587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.